AbbVie (ABBV) was in the news last week thanks to its agreements with Infinity Pharmaceuticals (INFI) and Calico. Keryx Biopharmaceuticals (KERX) was also in the headlines – the company’s shares declined despite receiving FDA approval for its oral, ferric iron-based compound. Gilead (GILD) was in the news as well, once again due to its hepatitis…
Alexion Pharmaceuticals’ (ALXN) sole marketed product is Soliris (eculizumab). Soliris is available for the treatment of two rare genetic disorders – paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. As the company is entirely dependent on Soliris for growth, it should look to avoid any setback related to the product. However, the FDA seems to…
Pipeline updates are highly awaited events in the pharma/biotech sector as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give an insight into the commercial potential of the candidate once it is successfully developed and commercialized. Earlier…
Shares of Gilead Sciences (NASDAQ GILD) dropped 1.4% to close the trading session on Sep 5 at $105.36 following a Bloomberg report claiming that the biopharmaceutical major will ink a licensing deal with generic players in order to make its blockbuster hepatitis C drug Sovaldi available in approximately 80 developing nations such as India and…
Prana Biotechnology shares surged 18.7% after the company announced that the FDA has granted orphan drug designation to its Huntington disease candidate, PBT2. We note that the FDA grants orphan drug designation to candidates being developed to treat rare diseases that affect less than 200,000 people in the U.S. The status makes the candidate eligible…
The FDA has approved Keryx Biopharmaceuticals, Inc’s (KERX) ferric citrate to control serum phosphorus levels in patients suffering from chronic kidney disease (CKD) on dialysis. However, the news adversely affected the stock price, which fell more than 5%, as the drug was approved with several warnings. Ferric citrate is not recommended for patients with an…
